How much funding has C2i Genomics raised?

C2i Genomics has raised $112.0M in total funding, most recently a Series B round.

Who are C2i Genomics's investors?

C2i Genomics's investors include Casdin Capital, NFX, The Mark Foundation for Cancer Research, Gordon Asset Management, LionBird.

When was C2i Genomics founded?

C2i Genomics was founded in 2019.

Where is C2i Genomics headquartered?

C2i Genomics is headquartered in New York, New York, United States.

What industry is C2i Genomics in?

C2i Genomics operates in Artificial Intelligence, Biotech, Healthcare.

How many employees does C2i Genomics have?

C2i Genomics has 11-50 employees.

C2i Genomics

Acquired

Cancer intelligence through AI and whole-genome sequencing

New York, United States · Founded 2019 · $112.0M raised

Artificial Intelligence

Biotech

Healthcare

Headquarters: New York, New York
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: c2i-genomics.com
Total Funding: $112.0M
Last Round: $100.0M Series BApr 2021
Rounds: 2

About

C2i Genomics developed a cloud-based cancer intelligence platform that applies artificial intelligence and whole-genome sequencing to liquid biopsy samples to detect minimal residual disease (MRD) in cancer patients. The company's C2-Intelligence Platform analyzes blood samples to provide highly precise cancer detection and treatment monitoring, enabling pharmaceutical and diagnostic organizations to track cancer recurrence and optimize treatment decisions. C2i partnered with AstraZeneca and Premier Inc. before being acquired by Veracyte in February 2024.

Summary

C2i Genomics is an Artificial Intelligence company based in New York, United States, founded in 2019. It has raised $112.0M in total across 2 rounds, most recently a $100.0M Series B round in Apr 2021. Investors include Casdin Capital, NFX and The Mark Foundation for Cancer Research.

LinkedIn X (Twitter)